Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $22.14

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $22.14.

A number of equities research analysts have issued reports on ACRV shares. JMP Securities assumed coverage on shares of Acrivon Therapeutics in a report on Friday, March 1st. They set a “mkt outperform” rating and a $14.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Acrivon Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 475,977 shares of the company’s stock valued at $2,342,000 after buying an additional 7,570 shares during the last quarter. Barclays PLC grew its position in Acrivon Therapeutics by 73.6% during the 4th quarter. Barclays PLC now owns 24,484 shares of the company’s stock worth $121,000 after purchasing an additional 10,384 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in Acrivon Therapeutics during the 4th quarter worth $157,000. Northern Trust Corp grew its position in Acrivon Therapeutics by 10.2% during the 4th quarter. Northern Trust Corp now owns 80,149 shares of the company’s stock worth $394,000 after purchasing an additional 7,427 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Acrivon Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 13,289 shares of the company’s stock worth $65,000 after purchasing an additional 3,370 shares during the last quarter. 71.62% of the stock is owned by hedge funds and other institutional investors.

Acrivon Therapeutics Stock Up 10.6 %

Acrivon Therapeutics stock opened at $7.15 on Tuesday. The firm has a market cap of $158.66 million, a PE ratio of -2.68 and a beta of 1.70. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $14.39. The company’s 50 day moving average is $4.63 and its two-hundred day moving average is $5.48.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.